221 CRESCENT STREET, WALTHAM, MA
Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
News, Material Contracts
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Spyre Therapeutics Enters Underwriting Agreement for $62.00 Share Offering
Investor Presentation
Spyre Therapeutics Reports $741 Million Cash as of March 31, 2026
Annual Report to Security Holders
Q1
FY 2024
Q3
Q2
Amended Quarterly Report
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
PRER14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Post-Effective Amendment to Registration Statement
Submission Upload
Correspondence